04
September 2024
EDX Medical
Group plc · EDX
AQSE:
EDX
("EDX
Medical" or the "Company")
Posting of Notice of AGM and
Annual Report
EDX Medical Group Plc (AQSE: EDX)
("EDX Medical" or the "Company"), which develops innovative digital
diagnostic products and services supporting personalised treatments
for cancer, heart disease and infectious diseases, announces that
its annual general meeting ("AGM") will be held at Mezzanine Room,
1 Wimpole Street, Westminster, London, W1G 0AE on 30 September 2024
at 2:00 p.m.
The annual report and financial
statements for the year ended 31 March 2024, Notice of AGM and Form
of Proxy will be posted today, 4 September 2024, to eligible
shareholders. Electronic copies will be shortly available on the
Company's website at: https://edxmedical.co.uk/documents/.
Contacts:
|
EDX
Medical Group Plc
|
|
|
Dr Mike Hudson (Chief Executive
Officer)
|
+44 (0)7812 345 301
|
|
|
|
|
Oberon Capital
|
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20 3179 5300
|
|
|
|
|
IFC
Advisory (Investor Relations)
|
|
|
Tim Metcalfe
|
+44 (0)20 3934 6630
|
|
Graham Herring
|
|
|
|
|
|
Media House International
|
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
Notes for
Editors:
About EDX Medical Group
EDX Medical Group Plc develops
innovative digital diagnostic products and services, enabling cost
effective and timely delivery of personalised treatment for cancer,
heart disease and infectious diseases. The company is now listed on
the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights
into pragmatic solutions combining advanced biological and digital
technologies, EDX Medical seeks to cost-effectively improve the
detection and characterisation of disease in order to personalise
treatment in a timely fashion. Early disease detection and
biologically-based personal treatment optimisation is considered to
be the most impactful way of reducing deaths and lowering the cost
of healthcare globally.
EDX Medical operates a
molecular biology and diagnostics laboratory in Cambridge, UK,
and 100%-owned subsidiaries "Hutano Diagnostics Ltd", based
in Oxford and "Torax Biosciences Ltd"
in Ireland which together are pioneering the development
of novel point of care tests.
EDX Medical conducts test
development and product validation to ISO 13485 and provides
testing and genomic sequencing services accredited to ISO 15189 by
the United Kingdom Accreditation
Service (UKAS).
www.edxmedical.co.uk
